

## PERSONAL INFORMATION

Johannes Hendrikus Ovelgonne

## WORK EXPERIENCE

- 
- 1989–1998 **various (post) doctoral research posts**  
Utrecht University (Netherlands)  
PhD in molecular biology, further research in molecular biology, veterinary pathology and virology
- 1998–2000 **Postdoctoral researcher, dept of mammalian virology**  
Institute for Animal Health ID-DLO (Netherlands)  
Development of recombinant vector vaccines for companion animals, development of diagnostic tools to differentiate between vaccine induced and disease induced immunity
- 2000–2003 **Scientist / biotech quality assessor**  
National Institute for Health and the Environment (RIVM) (Netherlands)  
- Assessor of registration dossiers for the medicines evaluation board (MEB): Chemical / pharmaceutical (quality) sections of biotechnological medicines dossiers.  
- OMCL batch-release program and development of release tests.  
- Biotech Working Party influenza breakout sessions  
- Member of CHMP Gene Therapy Expert Group.
- 2003–2006 **Senior Scientist**  
National Institute for Health and the Environment (RIVM) (Netherlands)  
Project lead of biotechnological medicines assessors team for the Netherlands Medicines Evaluation Board.  
Assessor for biotechnological medicinal products (specialisation: vaccines, recombinant DNA products, cell and gene therapy)  
Official batch release of investigational medicinal products (vaccines, immunological products, cell and gene therapy) for use in clinical trials.  
Core member of the EMEA Gene Therapy Working Party.  
National scientific advices for the Netherlands Medicines Evaluation Board.  
Participation in development of safety testing for gene therapy products.
- 2006–2009 **Head of department KBG (quality of biotechnological medicines)**  
National Institute for Health and the Environment (RIVM) (Netherlands)  
Head of the department KBG, which includes the biotechnological medicines assessors team for the Netherlands Medicines Evaluation Board.  
Member of the EMEA Scientific Advice Working Party,  
Member of the EMEA Gene Therapy Working Party
- 2009–April 2019 **member of scientific staff**  
Medicines Evaluation Board (MEB) (Netherlands)  
member of CAT  
member of SAWP
- April 2019–Present **member of scientific staff**  
Medicines Evaluation Board (MEB) (Netherlands)

member of CAT  
 member of SAWP  
 chairman of national advice group

## EDUCATION AND TRAINING

September 1982–March 1989 **MSC in Biology**  
 Wageningen Agricultural University (Netherlands)  
 biomechanics, insect physiology and cell biology

## ADDITIONAL INFORMATION

**Expertise** Biotechnology, molecular biology, virology, quality, genetically modified organisms, gene therapy

- Publications**
- 1: Ten Ham RMT, Hövels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH, Jedema I, Veld SAJ, Nikolic T, Van Pel M, Zwaginga JJ, Lin F, de Goede AL, Schreibelt G, Budde S, de Vries IJM, Wilkie GM, Dolstra H, Ovelgönne H, Meij P, Mountford JC, Turner ML, Hoefnagel MHN. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. *Cytotherapy*. 2020 Jul;22(7):388-397. doi: 10.1016/j.jcyt.2020.03.432. Epub 2020 May 12. PMID: 32414635
  - 2: Narayanan G, Cossu G, Galli MC, Flory E, Ovelgonne H, Salmikangas P, Schneider CK, Trouvin JH. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. *Hum Gene Ther Clin Dev*. 2014 Mar;25(1):1-6. doi: 10.1089/humc.2013.230. Review. PubMed PMID: 24649836.
  - 3: Committee for Advanced Therapies (CAT); CAT Scientific Secretariat, Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancs J, Maciulaitis R, Robert JL, Samuel A, Ovelgonne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turcani P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schuessler-Lenz M, Kokkas V, Buzacs Z, MacAleenan N, Galli MC, Line A, Gulbinovic J, Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko M, Marinko P, Timn M, Cheng W, Crosbie GA, Meade N, di Paola ML, VandenDriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Blattel I, Celis P. Challenges with advanced therapy medicinal products and how to meet them. *Nat Rev Drug Discov*. 2010 Mar;9(3):195-201. doi: 10.1038/nrd3052. Review. PubMed PMID: 20190786.
  - 4: Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgonne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. *Hum Vaccin*. 2006 Mar-Apr;2(2):45-53. Epub 2006 Mar 16. Review. PubMed PMID: 17012886.
  - 5: Schalk JA, van den Elzen C, Ovelgonne H, Baas C, Jongen PM. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR. *J Virol Methods*. 2004 May;117(2):179-87. PubMed PMID: 15041215.
  - 6: Malago JJ, Koninkx JF, Ovelgonne HH, van Asten FJ, Swennenhuis JF, van Dijk JE. Expression levels of heat shock proteins in enterocyte-like Caco-2 cells after exposure to *Salmonella enteritidis*. *Cell Stress Chaperones*. 2003 Summer;8(2):194-203. PubMed PMID: 14627205; PubMed Central PMCID: PMC514871.
  - 7: Ovelgonne JH, Landman WJ, Gruys E, Gielkens AL, Peeters BP. Identical amyloid precursor proteins in two breeds of chickens which differ in susceptibility to develop amyloid arthropathy. *Amyloid*. 2001 Mar;8(1):41-51. PubMed PMID: 11293824.
  - 8: Ovelgonne JH, Koninkx JF, Pusztai A, Bardocz S, Kok W, Ewen SW, Hendriks HG, van Dijk JE. Decreased levels of heat shock proteins in gut epithelial cells after exposure to plant lectins. *Gut*. 2000 May;46(5):679-87. PubMed PMID: 10764712; PubMed Central PMCID: PMC1727920.
  - 9: Ovelgonne JH, Van Wijk R, Verkleij AJ, Post JA. Cultured neonatal rat heart cells can be preconditioned by ischemia, but not by heat shock. The role of stress proteins. *J Mol Cell Cardiol*. 1996 Aug;28(8):1617-29. PubMed PMID: 8877772.
  - 10: Ovelgonne H, Bitorina M, Van Wijk R. Stressor-specific activation of heat shock genes in H35 rat hepatoma cells. *Toxicol Appl Pharmacol*. 1995 Nov;135(1):100-9. PubMed PMID: 7482529.
  - 11: Ovelgonne H, Van Wijk R. Modulation of HSP68 gene expression after heat shock in

thermosensitized and thermotolerant cells is not solely regulated by binding of HSF to HSE. *Int J Hyperthermia*. 1995 Sep-Oct;11(5):719-32. PubMed PMID: 7594822.

12: Ovelgonne JH, Souren JE, Wiegant FA, Van Wijk R. Relationship between cadmium-induced expression of heatshock genes, inhibition of protein synthesis and cell death. *Toxicology*. 1995 May 5;99(1-2):19-30. PubMed PMID: 7761999.

13: Ovelgonne HH, Wiegant FA, Souren JE, Van Rijn H, Van Wijk R. Enhancement of the stress response by low concentrations of arsenite in arsenite-pretreated Reuber H35 hepatoma cells. *Toxicol Appl Pharmacol*. 1995 May;132(1):146-55. PubMed PMID: 7747278.

14: van Wijk R, Ovelgonne JH, de Koning E, Jaarsveld K, van Rijn J, Wiegant FA. Mild step-down heating causes increased levels of HSP68 and of HSP84 mRNA and enhances thermotolerance. *Int J Hyperthermia*. 1994 Jan-Feb;10(1):115-25. PubMed PMID: 8144983.

15: Van Wijk R, Welters M, Souren JE, Ovelgonne H, Wiegant FA. Serum-stimulated cell cycle progression and stress protein synthesis in C3H10T1/2 fibroblasts treated with sodium arsenite. *J Cell Physiol*. 1993 May;155(2):265-72. PubMed PMID: 8482719.

16: Ovelgonne JH, Bol AW, Hop WC, van Wijk R. Mechanical agitation of very dilute antiserum against IgE has no effect on basophil staining properties. *Experientia*. 1992 May 15;48(5):504-8. PubMed PMID: 1376282.

#### Projects

Memberships British Pharmacological Society

#### Other Relevant Information